Santa Ana Bio

Current therapies cannot precisely eliminate specific immune cell populations, leading to ineffective treatment and unwanted immune side effects in immune-mediated diseases.

The company develops engineered antibody therapies that selectively target and deplete specific immune cells.

Biopharma companies and clinicians treating patients with immune-mediated diseases who need targeted immune cell depletion therapies.